ADDIN EN.CITE (34)Clinical trials are needed to determine if current and emerging treatments targeting endothelin-1, nitric oxide synthesis, prostacyclin, serotonin, and peroxisome proliferator-activated receptor g can improve outcomes for select patients with CKD-associated pulmonary hypertension. Here, EDN1 is linked to pulmonary arterial hypertension.